Literature DB >> 27697839

Heparan Sulfate Regulates the Structure and Function of Osteoprotegerin in Osteoclastogenesis.

Miaomiao Li1, Shuying Yang1, Ding Xu2.   

Abstract

Osteoprotegerin (OPG), a decoy receptor secreted by osteoblasts, is a major negative regulator of bone resorption. It functions by neutralizing the receptor activator of nuclear factor κB ligand (RANKL), which plays a central role in promoting osteoclastogenesis. OPG is known to be a high-affinity heparan sulfate (HS)-binding protein. Presumably, HS could regulate the function of OPG and affect how it inhibits RANKL. However, the molecular detail of HS-OPG interaction remains poorly understood, which hinders our understanding of how HS functions in osteoclastogenesis. Here we report mapping of the HS-binding site of OPG. The HS-binding site, identified by mutagenesis study, consists of eight basic residues that are located mostly at the junction of the second death domain and the C-terminal domain. We further show that heparin-derived dodecasaccharide is able to induce dimerization of OPG monomers with a stoichiometry of 1:1. Small-angle X-ray scattering analysis revealed that upon binding of HS, OPG undergoes a dramatic conformational change, resulting in a more compact and less flexible structure. Importantly, we present here three lines of evidence that HS, OPG, and RANKL form a stable ternary complex. Using a HS binding-deficient OPG mutant, we further show that in an osteoblast/bone marrow macrophage co-culture system, immobilization of OPG by HS at the osteoblast cell surface substantially lowers the inhibitory threshold of OPG toward RANKL. These discoveries strongly suggest that HS plays an active role in regulating OPG-RANKL interaction and osteoclastogenesis.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  RANKL; conformational change; dimerization; heparan sulfate; osteoblast; osteoclastogenesis; osteoprotegerin; small-angle X-ray scattering (SAXS); ternary complex

Mesh:

Substances:

Year:  2016        PMID: 27697839      PMCID: PMC5104940          DOI: 10.1074/jbc.M116.751974

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Authors:  E Tsuda; M Goto; S Mochizuki; K Yano; F Kobayashi; T Morinaga; K Higashio
Journal:  Biochem Biophys Res Commun       Date:  1997-05-08       Impact factor: 3.575

2.  Regulators of G protein signaling 12 promotes osteoclastogenesis in bone remodeling and pathological bone loss.

Authors:  X Yuan; J Cao; T Liu; Y-P Li; F Scannapieco; X He; M J Oursler; X Zhang; J Vacher; C Li; D Olson; S Yang
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

3.  Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

Authors:  W S Browner; L Y Lui; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK.

Authors:  S Théoleyre; S Kwan Tat; P Vusio; F Blanchard; J Gallagher; S Ricard-Blum; Y Fortun; M Padrines; F Rédini; D Heymann
Journal:  Biochem Biophys Res Commun       Date:  2006-06-30       Impact factor: 3.575

6.  Osteoblast isolation from murine calvaria and long bones.

Authors:  Astrid D Bakker; Jenneke Klein-Nulend
Journal:  Methods Mol Biol       Date:  2012

7.  Characterization of structural domains of human osteoclastogenesis inhibitory factor.

Authors:  K Yamaguchi; M Kinosaki; M Goto; F Kobayashi; E Tsuda; T Morinaga; K Higashio
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

8.  Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.

Authors:  N Udagawa; N Takahashi; H Yasuda; A Mizuno; K Itoh; Y Ueno; T Shinki; M T Gillespie; T J Martin; K Higashio; T Suda
Journal:  Endocrinology       Date:  2000-09       Impact factor: 4.736

9.  Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation.

Authors:  Vannakambadi K Ganesh; Scott A Smith; Girish J Kotwal; Krishna H M Murthy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-03       Impact factor: 11.205

10.  Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

Authors:  Therese Standal; Carina Seidel; Øyvind Hjertner; Torben Plesner; Ralph D Sanderson; Anders Waage; Magne Borset; Anders Sundan
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

View more
  13 in total

1.  Antiresorptive activity of osteoprotegerin requires an intact heparan sulfate-binding site.

Authors:  Miaomiao Li; Ding Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-07       Impact factor: 11.205

2.  Dimerization interface of osteoprotegerin revealed by hydrogen-deuterium exchange mass spectrometry.

Authors:  Yiming Xiao; Miaomiao Li; Rinzhi Larocque; Fuming Zhang; Anju Malhotra; Jianle Chen; Robert J Linhardt; Lars Konermann; Ding Xu
Journal:  J Biol Chem       Date:  2018-09-25       Impact factor: 5.157

3.  Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass.

Authors:  Satoshi Nozawa; Toshihiro Inubushi; Fumitoshi Irie; Iori Takigami; Kazu Matsumoto; Katsuji Shimizu; Haruhiko Akiyama; Yu Yamaguchi
Journal:  JCI Insight       Date:  2018-02-08

4.  Effects of the TNFRSF11B Mutation Associated With Calcium Pyrophosphate Deposition Disease in Osteoclastogenesis in a Murine Model.

Authors:  Elizabeth Mitton-Fitzgerald; Claudia M Gohr; Charlene J Williams; Amaryllis Ortiz; Gabriel Mbalaviele; Ann K Rosenthal
Journal:  Arthritis Rheumatol       Date:  2021-06-08       Impact factor: 15.483

5.  Hypercholesterolemia in Progressive Renal Failure Is Associated with Changes in Hepatic Heparan Sulfate - PCSK9 Interaction.

Authors:  Pragyi Shrestha; Saritha Adepu; Romain R Vivès; Rana El Masri; Astrid Klooster; Fleur Kaptein; Wendy Dam; Stephan J L Bakker; Harry van Goor; Bart van de Sluis; Jacob van den Born
Journal:  J Am Soc Nephrol       Date:  2021-03-23       Impact factor: 14.978

6.  Mesenchymal Cell-Derived Juxtacrine Wnt1 Signaling Regulates Osteoblast Activity and Osteoclast Differentiation.

Authors:  Fan Wang; Kati Tarkkonen; Vappu Nieminen-Pihala; Kenichi Nagano; Rana Al Majidi; Tero Puolakkainen; Petri Rummukainen; Jemina Lehto; Anne Roivainen; Fu-Ping Zhang; Outi Mäkitie; Roland Baron; Riku Kiviranta
Journal:  J Bone Miner Res       Date:  2019-03-07       Impact factor: 6.741

7.  The heparan sulfate proteoglycan Syndecan-1 influences local bone cell communication via the RANKL/OPG axis.

Authors:  Melanie Timmen; Heriburg Hidding; Martin Götte; Thaqif El Khassawna; Daniel Kronenberg; Richard Stange
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

8.  Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption.

Authors:  Keisha M Cawley; Nancy Cecile Bustamante-Gomez; Anveshi G Guha; Ryan S MacLeod; Jinhu Xiong; Igor Gubrij; Yu Liu; Robin Mulkey; Michela Palmieri; Jeff D Thostenson; Joseph J Goellner; Charles A O'Brien
Journal:  Cell Rep       Date:  2020-09-08       Impact factor: 9.423

9.  Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.

Authors:  Sébastien S Dufresne; Antoine Boulanger-Piette; Sabrina Bossé; Anteneh Argaw; Dounia Hamoudi; Laetitia Marcadet; Daniel Gamu; Val A Fajardo; Hideo Yagita; Josef M Penninger; A Russell Tupling; Jérôme Frenette
Journal:  Acta Neuropathol Commun       Date:  2018-04-24       Impact factor: 7.801

10.  Regulator of G protein signaling 12 enhances osteoclastogenesis by suppressing Nrf2-dependent antioxidant proteins to promote the generation of reactive oxygen species.

Authors:  Andrew Ying Hui Ng; Ziqing Li; Megan M Jones; Shuting Yang; Chunyi Li; Chuanyun Fu; Chengjian Tu; Merry Jo Oursler; Jun Qu; Shuying Yang
Journal:  Elife       Date:  2019-09-06       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.